Accelerator
Meeting Point
{AMP IV}

Fourth Edition (16th December 2021)

VIRTUAL

From bench to Market:
The Accelerator Meeting Point
drives the biomedical
innovation in Bellvitge

The AMP IV is organised by IDIBELL’s Business Development & Innovation Area and aims to offer lifescience companies and investors a preferential access to innovative projects at different stages of development.

The innovative projects presented will cover the following fields: oncology, regenerative medicine, mental health, metabolic diseases, infectious diseases (COVID-19) and sepsis. The proposed solutions will include assets in drug development, diagnostic and medical devices from digital therapeutics technologies

0
Projects
+ 0
Attendees
+
B2B Meetings

Projects

ROOM 1

APTADEL: RNA Aptamer technology for the treatment of Ewing Sarcoma

(Dr. Oscar Martínez / IDIBELL)

First-in-Class anticancer treatment with its patient selection biomarker to overcome tumor progression in advanced cancer patients

(Dr. Oriol Casanovas and Dra. Gabriela Jiménez / IDIBELL – ICO)

SUCCIPRO: First-in-class therapy for inflammatory and metabolic diseases

(Dr. Isabel Huber Ruano / IISPV)

LoopDx: A novel first-in-class in vitro cellular immunoassay that identifies sepsis after the first-hour of bloodstream infection

(Dr. Enrique Hernandez / LoopDx))

KronoSafe® Temporary Pacemaker Fixation System

(Dr. Ray Vicente Miralles  / ISABIAL))

T-Cell Therapeutics

(Dr. Bernat Soria / ISABIAL)

Endoscopic Smart Center

(Dr. Lucas Rovira Soriano / IIS La Fe)

Repositioning of a drug for spinal muscular atrophy

(Dr. Piotr Tadeusz Konieczny / INCLIVA)

Saving lives by reducing hospital mortality from sepsis and other acute inflammatory processes.

(Dr. Pablo Pelegrín, Dr. Carlos García, Sr. Joaquín Gómez / IMIB)

ROOM 2

Regeneration Of Sinusoidal Niches To Preserve Hematopoiesis After Chemotherapy On Ageing

(Dra. Carolina Florian / IDIBELL

Dna Damage Repair Deficit In Cancer Cells

(Dr. Miquel Angel Pujana / IDIBELL -ICO

Therapy in your Pocket: Effectiveness of Serious Games in Behavioral Addictions (GAME4HEALTH)

(Dra. Susana Jiménez / IDIBELL- HUB

Inhibition of the miR-424/503 cluster to improve reprogramming efficiency for the generation of iPSCs

(Dr. David Llobet and Dra. Ruth Rodríguez / IDIBELL and IDIBELL- UB)

Tackling radiation-induced enteritis

(Dr. Jordi Guiu / IDIBELL)

PPAR-alpha/gamma AGONISTS

(Dra. Nuria Cabedo Escrig / INCLIVA)

aCUP-E: Advance Cup Electrode for Newborns

(Dr. Albert Fabregat and Dr. Vicenç Pascual / IISPV and URV)

NYSTAREC: Development of a new device to diagnose and treat benign paroxysmal positional vertigo in primary care and emergency departments

(Dr. Josep Lluis Ballvé / IDIAP)

Prostact. Prostate palpation device for prostate cancer screening.

(Dr. César David Vera Donoso / IIS La Fe )

Device for UCI Patients

(Dra. Gemma Via / IDIBELL )

Agenda

This fourth edition will be VIRTUAL, and the conference will consist in two rooms, dividing the projects according to their state of development, establishing 10 projects per room with a total of 20 in the event.

 The Investment room mainly dominated by investors and the R + D / Collaboration room will be highlighted by the presence of biotechnology and health sector companies.

At the end of the projects presentations in front of the investors and companies, there is the possibility of selecting the projects that have raised their interest, and B2B meeting will be scheduled to their availability in the following days.

09:00
Opening and Welcome:

Gabriel Capellá, IDIBELL Director


09:00
09:15
Project Pitching Sesion 1
  • Virtual Room 1 (Investment):

  • 9:35h - First-in-Class anticancer treatment with its patient selection biomarker to overcome tumor progression in advanced cancer patients.

    9:55h - SUCCIPRO: First-in-class therapy for type 2 diabetes

    10:15h - LoopDx: A novel first-in-class in vitro cellular immunoassay that identifies sepsis after the first-hour of bloodstream infection

    10:35h - T-Cell: Therapeutics
  • Virtual Room 2 (R+D / Collaboration)

    • 9:15h - Regeneration of Sinusoidal niches to preserve hematopoiesis after chemotherapy on ageing

      9:35h - PPAR-alpha/gamma Agonists

      9:55h - Therapy in your pocket: Effectiveness of serious games in behavioral addictions (GAME4HEALTH)

      10:15h - Inhibition of the miRNA-424/503 cluster to improve reprogramming efficiency for the generation of iPSCs

      10:35h - Prostact: Postate palpation device for prostate cancer screening
    09:15
    11:00
    Break
    11:00
    11:15
    Project Pitching Sesion 2
    • Virtual Room 1 (Investment):

    • 11:10h - Repositioning of a drug for spinal muscular atrophy

      11:30h - KronoSafe® Temporary Pacemaker Fixation System

      11:50h - Endoscopic Smart Center

      12:10h - Saving lives by reducing hospital mortality from sepsis and other acute inflammatory processes

      12:30h - APTADEL: Pre-clinical stage drug development biotech company based on RNA Aptamer technology for the treatment of cancer.
    • Virtual Room 2 (R+D/Collaboration):

    • 11:10h - Boosting intestinal regeneration to tackle enteritis

      11:30h - aCUP-E: Advance Cup Electrode for Newborns

      11:50h - Development of a new device to diagnose and treat benign paroxysmal positional vertigo in primary care and emergency departments: NYSTAREC Project.

      12:10h - DNA Damage Repair Deficit In Cancer Cells

      12:30h - Device for UCI Patients
    11:15
    13:00
    Closing & B2B meetings
    (Will be scheduled in the following days according to your interest and availability in the following days)
    13:00

    Previous editions

    2020

    AMP III (3rd edition)

    The most innovative technology projects in the healthcare sector were presented this November 26th at the third edition of the AMP III organized by the Business Development and Innovation Area of the Bellvitge Biomedical Research Institute (IDIBELL). An event that this time has been held virtually to ensure the safety of all participants. The digital meeting allowed different IDIBELL entrepreneurs and invited entities from the HealthTech/Biotech sector to espouse their projects to investors and pharmaceutical companies to obtain financing.

    RESEARCHERS 2020

    Dr. Oriol Casanovas

    Dr. Josep Maria Aran

    Dr. Oscar Martinez-Tirado

    Dr. Rafael Mañez

    Dr. Manel Cascalló

    Dr. Joan Gilavert

    Dra. Antonella Consiglio

    Dra. Sara Larriba

    Dr. Thomas Golda

    Dr. David Garcia Molleví

    Dra. Ethelvina Queralt

    Dr. Jordi Guiu

    Dra. Bárbara Rivera Polo

    Dr. José Expósito Ollero (INCLIVA)

    Dra. Clara Gomez (FISABIO)

    Dr. Jose Alberola / Roberto García (IIS La Fe)

    Dr. José Luis García Gimenez (INCLVA)

    Dr. Xavier Ruiz Plazas (IISPV)

    Dr. Roberto de la Rica (IdisBa)

    GUESTS 2020

    More than 20 companies from the sector participated in the virtual meeting: 12 venture capital companies and investors, 7 pharmaceutical and biotechnology companies, and 3 regulatory and consulting agencies as a panel of experts to assess the feasibility of the projects and obtain their valuable feedback.

    Among the companies participating in the panel of experts, this third edition stands out for the presence of international investors, such as Aurora Science and Gimv. At the local level, we could have the feedback from an investment fund such as In vivo Capital Partners or Canaan Research and Investment, as well as from DDR at the regulatory level.

    2019

    AMP II (2nd edition)

    Bellvitge Biomedical Research Institute (IDIBELL) celebrated the second edition of its Accelerator
    Meeting Point (AMP), restating the success of the previous edition. This meeting is organised by IDIBELL’s business development and innovation area and aims to offer investors preferential access to innovation projects in their early stages.

    RESEARCHERS 2019

    Dr. Oriol Casanovas

    Dr. Josep Maria Aran

    Dr. Josep Maria Grinyó

    Dra. Ethel Queralt

    Dra. Maria Jose Linares

    Dr. Angel Raya

    Dr. Oscar Martinez-Tirado

    Dra. Virginia Nunes

    Dra. Eva Gonzalez

     

    GUESTS 2019

    Jordi Naval – BIOCAT
    Michael Tadrós – Fundación Botín
    Raül Delgado-Morales – IDIBELL
    Marina Rigau Resina – IDIBELL
    Esther Riambau – UPF
    Laura Rodríguez Gallego – Healthequity
    Ignasi Eras – Nina Capital
    Melqui Calzado- CataloniaBio
    Andrea Sáez – ASABYS
    Sylvain Sachot – ASABYS
    Lucas Martinez – DCN
    Yuki Hasegawa – Whiz partners
    Christoph Massner – Earlybird
    Jöel Jean-Mairet  – Ysios
    Mireia Angulo Parera  – Caixa C.R.
    Sara Sanz – Inveready
    Skyla Rabadi – Ship2B
    Marc Ramis – Life BioScience
    Francisco Armero – Cross Road Biotech
    Pablo Cabello – Clave Mayor

    2018

    AMP I (1st edition)

    The Bellvitge Biomedical Research Institute (IDIBELL) held yesterday April 16th the first edition of its
    Accelerator Meeting Point, a meeting where CataloniaBio -association of biomedicine and health
    companies in Catalonia-, Biocat -institution responsible for the promotion of the life sciences and
    health sector in Catalonia- and Health Equity -Venture capital of the Barcelona Medical Associationspent
    a day with researchers in order to provide recommendations for research projects at a stage
    two to three years prior to reaching a commercial milestone.

    RESEARCHERS 2018

    Dr. Carles Soriano

    Dra. Monica  Povedano

    Dra. Sara Larriba

    Dra. Eva Gonzalez

    Dr. Daniel Lorenzo

    Dr. Josep Maria Aran

    Dr. Francisco Ciruela

    Dra. Mariona Graupera

    Dr. Oriol Casanovas

    Dr. Àngel Raya

    Dra. Àngels Fabra

     

    GUESTS 2018

    CataloniaBio

    Biocat

    Health Equity 

    Chasing Science

    Universal Doctor

    With the aim of strengthening the future Mediterranean alliance AIISEM (Alianza de Innovación e Industralización Sanitaria del Eje Mediterráneo), the fourth edition of the AMP will also count with the participation projects from the following research centers/institutions: ISABIAL, IDIAP, FISABIO, INCLIVA, IIS la Fe, IMIB and IISPV.

    Team

    Innovation & Business Development Team

    Mario de la Cuesta 

    Head of Innovation Portfolio 

    Gisela Gallego 

    Commercialization Unit Senior Officer

    Marta Castillejo 

    Innovation Portfolio Project Manager

    Isaac Aran

    Commercialization Unit Officer 

    Laia Traveset

    Innovation Portfolio Project Manager 

    Contact

    Innovation & Business Development Area

    C/ Feixa Llarga, s/n  08907 L'Hospitalet de Llobregat (Barcelona) 

    Tef. 932 607 775 ext. 3309
    innovacio@idibell.cat